Research Comparison
Tirzepatide vs Retatrutide: Dual vs Triple Agonist Comparison
Tirzepatide and retatrutide represent the second and third generations of multi-receptor incretin peptides. Tirzepatide targets GIP and GLP-1 receptors, while retatrutide adds the glucagon receptor as a third target.
Receptor Pharmacology
Tirzepatide is a 39-amino-acid dual agonist primarily targeting the GIP receptor with secondary GLP-1R cross-reactivity. SURMOUNT-1 (Jastreboff et al. 2022, PMID: 35658024) reported 15-20.9% weight reductions at 72 weeks.
Retatrutide adds glucagon receptor agonism to the GIP/GLP-1 mechanism. Jastreboff et al. (2023, PMID: 37366315) reported −24.2% at the 12mg dose in the phase 2 trial at 48 weeks.
Frequently Asked Questions
What is the difference between tirzepatide and retatrutide?+
Research Use Only
FOR RESEARCH USE ONLY. Products sold by Healthy Aminos are intended strictly for in-vitro research and laboratory use. Not for human or animal consumption. Not FDA approved. By purchasing from Healthy Aminos, the buyer acknowledges that these products are not intended to diagnose, treat, cure, or prevent any disease. All products are sold as reference standards and research chemicals only.